Clinical hematology international最新文献_第3页

Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy. 处理嵌合抗原受体 T 细胞 (CAR-T) 疗法的感染并发症。

Clinical hematology international Pub Date : 2024-04-29 eCollection Date: 2024-01-01 DOI: 10.46989/001c.115932

Nausheen Ahmed, Olalekan Oluwole, Zahra Mahmoudjafari, Nahid Suleman, Joseph P McGuirk

{"title":"Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.","authors":"Nausheen Ahmed, Olalekan Oluwole, Zahra Mahmoudjafari, Nahid Suleman, Joseph P McGuirk","doi":"10.46989/001c.115932","DOIUrl":"10.46989/001c.115932","url":null,"abstract":"Chimeric antigen receptor T-cell (CAR T-cell) therapy has changed the paradigm of management of non-Hodgkin's lymphoma (NHL) and Multiple Myeloma. Infection complications have emerged as a concern that can arise in the setting of therapy and lead to morbidity and mortality. In this review, we classified infection complications into three categories, pre-infusion phase from the time pre- lymphodepletion (LD) up to day zero, early phase from day of infusion to day 30 post-infusion, and late phase after day 30 onwards. Infections arising in the pre-infusion phase are closely related to previous chemotherapy and bridging therapy. Infections arising in the early phase are more likely related to LD chemo and the expected brief period of grade 3-4 neutropenia. Infections arising in the late phase are particularly worrisome because they are associated with adverse risk features including prolonged neutropenia, dysregulation of humoral and adaptive immunity with lymphopenia, hypogammaglobinemia, and B cell aplasia. Bacterial, respiratory and other viral infections, protozoal and fungal infections can occur during this time . We recommend enhanced supportive care including prompt recognition and treatment of neutropenia with growth factor support, surveillance testing for specific viruses in the appropriate instance, management of hypogammaglobulinemia with repletion as appropriate and extended antimicrobial prophylaxis in those at higher risk (e.g. high dose steroid use and prolonged cytopenia). Finally, we recommend re-immunizing patients post CAR-T based on CDC and transplant guidelines.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11086990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias – A Single Centre Experience. 单中心经验：亚洲浆细胞瘤患者对达拉单抗的耐受性

Clinical hematology international Pub Date : 2024-01-16 DOI: 10.46989/001c.92085

A. Tso, S. Wang, C. Gallardo, D. Christopher, K. Ong

{"title":"Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias – A Single Centre Experience.","authors":"A. Tso, S. Wang, C. Gallardo, D. Christopher, K. Ong","doi":"10.46989/001c.92085","DOIUrl":"https://doi.org/10.46989/001c.92085","url":null,"abstract":"Daratumumab is increasingly incorporated into the standard treatment regimens for patients with plasma cell dyscrasias in Asia, especially with cost-containment measures implemented by various regional health authorities. This analysis aimed to study daratumumab’s tolerability amongst Asian patients. This is a retrospective medical records review of patients who received daratumumab between November 2016 and August 2021 as part of routine clinical care. Sixty-two patients were included in the study: 62.9% had renal impairment, and 27.4% had creatinine clearance (CrCl) <30ml/min. Forty-five patients (72.6%) received daratumumab combination therapy, with a median 1 line of prior therapy. The median duration of follow-up was 12.4 months, and the median duration patients were on treatment with daratumumab was 12.3 months. Twenty-one of 62 (33.9%) patients experienced infusion-related reactions (IRRs) after the first dose of intravenous daratumumab. Seven developed mostly grades 1 and 2 respiratory events, and 14 showed grades 1 and 2 non-respiratory IRRs. Only one patient experienced a grade 1 IRR with the second infusion, with none developing any IRRs in the third or subsequent infusions. Eight (12.9%) patients were affected by hematological adverse events (AEs), mostly grades 2 and 3, with one experiencing grade-4 neutropenia without sepsis. Six (9.7%) patients experienced non-hematological AEs, the commonest being pneumonia and other infections, with one developing Nocardia pneumonia (grade 4) 14 months after the initiation of daratumumab. In conclusion, daratumumab is tolerable amongst Asian patients, including the elderly, and patients with severe renal impairment and chronic lung diseases.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139618366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are We Ready For "Triplet" Therapy in Higher-Risk MDS? 我们准备好接受高危MDS的“三联”治疗了吗？

Clinical hematology international Pub Date : 2023-11-03 eCollection Date: 2023-01-01 DOI: 10.46989/001c.88301

Andrew M Brunner, Uwe Platzbecker, Amy E DeZern, Amer M Zeidan

引用次数: 0

Hottest topics in hematopoietic stem cell transplantation: a summary from the 8th International Transplant and Cellular Therapy Course. 造血干细胞移植最热门话题：第八届国际移植与细胞治疗课程综述。

Clinical hematology international Pub Date : 2023-10-18 eCollection Date: 2023-01-01 DOI: 10.46989/001c.89034

Edwin U Suárez

引用次数: 0

Walter Michael Kuehl, MD - October 25, 1939 - April 30, 2023 Walter Michael Kuehl，医学博士，1939年10月25日- 2023年4月30日

Clinical hematology international Pub Date : 2023-09-19 DOI: 10.46989/001c.87881

Leif Bergsagel

引用次数: 0

Standing on the Shoulders of the Giants: Dr. Alain Fischer. 站在巨人队的肩膀上：阿兰·菲舍尔博士。

Clinical hematology international Pub Date : 2023-09-16 eCollection Date: 2023-01-01 DOI: 10.46989/001c.87882

Mohamad Mohty, Alain Fischer

引用次数: 0

Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States. 美国住院患者浆细胞白血病结局的种族差异。

Clinical hematology international Pub Date : 2023-09-08 eCollection Date: 2023-01-01 DOI: 10.46989/001c.87755

Cindy Wu, Deepa Dongarwar, Samer Al Hadidi

{"title":"Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States.","authors":"Cindy Wu, Deepa Dongarwar, Samer Al Hadidi","doi":"10.46989/001c.87755","DOIUrl":"https://doi.org/10.46989/001c.87755","url":null,"abstract":"Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma (MM) with a poor prognosis. Prior studies have shown that racial disparities affect MM patients in various ways, which may affect patients' outcomes. In this study, we aimed to investigate racial differences in hospitalization outcomes for PCL using Nationwide Inpatient Sample data. Overall, hospitalization rates for PCL tended to decrease over the past decade. Among hospitalized patients with a primary diagnosis of PCL, there was no statistically significant association between race/ethnicity and hospitalization rates, between NH-White patients and NH-Black patients (OR 1.94; 95%CI 0.3-3.54, p 0.95), and Hispanic patients (OR 0.47; 95% CI 0.05-4.23, p 0.5). Additionally, there was no significant association between race/ethnicity and inpatient mortality. The overall lower incidence of PCL, more significant disease burden, and poor prognosis across all groups may contribute to our findings. With increasing evidence that PCL is cytogenetically distinct from MM, more investigation into biological and sociodemographic factors that affect healthcare utilization and treatment outcomes should be carried out.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/20/chi_2023_5_4_87755.PMC10515655.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand? Ruxolitinib在难治性/复发性霍奇金淋巴瘤治疗中的应用：我们的立场？

Clinical hematology international Pub Date : 2023-08-28 eCollection Date: 2023-01-01 DOI: 10.46989/001c.87501

Ahmed H Al Sharie, Balqis M Abu Mousa, Ahmad O Alomari

引用次数: 0

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma 多发性骨髓瘤患者脊髓压迫相关住院治疗的种族差异

Clinical hematology international Pub Date : 2023-02-03 DOI: 10.46989/001c.87569

Samer Al Hadidi, Deepa Dongarwar, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D. Shaughnessy, Frits van Rhee

引用次数: 0

Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation 造血干细胞移植后单核细胞重建和肠道菌群组成

Clinical hematology international Pub Date : 2019-09-20 DOI: 10.1101/777268

S. Morjaria, Allen W. Zhang, Sohn G. Kim, J. Peled, Simone Becattini, E. Littmann, E. Pamer, M. Perales, Michael C. Abt

{"title":"Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation","authors":"S. Morjaria, Allen W. Zhang, Sohn G. Kim, J. Peled, Simone Becattini, E. Littmann, E. Pamer, M. Perales, Michael C. Abt","doi":"10.1101/777268","DOIUrl":"https://doi.org/10.1101/777268","url":null,"abstract":"Monocytes are an essential cellular component of the innate immune system that support the host’s effectivenss to combat a range of infectious pathogens. Hemopoietic cell transplantation (HCT) results in transient monocyte depletion, but the factors that regulate recovery of monocyte populations are not fully understood. In this study, we investigated whether the composition of the gastrointestinal microbiota is associated with the recovery of monocyte homeostasis after HCT. Methods We performed a single-center, prospective, pilot study of 18 recipients of either autologous or allogeneic HCT. Serial blood and stool samples were collected from each patient during their HCT hospitalization. Analysis of the gut microbiota was done using 16S rRNA gene sequencing and flow cytometric analysis was used to characterize the phenotypic composition of monocyte populations. Results Dynamic fluctuations in monocyte reconstitution occurred after HCT and large differences were observed in monocyte frequency among patients over time. Recovery of absolute monocyte counts and monocyte subsets showed significant variability across the heterogeneous transplant types and conditioning intensities; no relationship to the microbiota composition was observed in this small cohort. Conclusion A relationship between the microbiota composition and monocyte homeostasis could not be firmly established in this pilot study.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73184002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5